BioPharmSignal logoBioPharmSignal

Biotech News

Biofrontera Inc. to Report Third Quarter 2026 Financial Results on November 13, 2026

Biofrontera Inc (BFRI)Biofrontera IncEarnings

Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a U.S.-based biopharmaceutical company engaging in the development, manufacturing, and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy, today announced that it will report financial results for the third quarter ended September 30, 2026 before the market opens on Friday, November 13, 2026.

Related news

BFRIBiofrontera Inc2025-11-06 21:01 EST

Biofrontera Inc. to Report Third Quarter 2025 Financial Results on November 12, 2025 and Host a Conference Call on November 13, 2025

BFRIBiofrontera Inc2026-08-05 20:15 EST

Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026

View all latest news

Biofrontera Inc

Dermatology Photodynamic Therapy Biofrontera commercializes photodynamic therapy products for dermatologic disease in the United States. Its principal platform combines Ameluz, a topical photosensitizer, with the RhodoLED illumination system. Actinic Keratosis Franchise Ameluz is established in actinic keratosis and is being developed...

Recent company news

BFRIBiofrontera Inc2026-11-06 23:08 EST

Biofrontera Inc. to Report Third Quarter 2026 Financial Results on November 13, 2026

BFRIBiofrontera Inc2026-10-08 13:22 EST

Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body

BFRIBiofrontera Inc2026-09-14 13:26 EST

Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma

BFRIBiofrontera Inc2026-08-13 12:51 EST

Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth

BFRIBiofrontera Inc2026-08-05 20:15 EST

Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026

Stock data

Close
0.81 USD
Market cap
13.19M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States